Olivier O Delattre

List of Publications by Year
in descending order

325 papers	37,364 citations	3919 88 h-index	3476 182 g-index
343 all docs	343 docs citations	343 times ranked	35807 citing authors

#	Article	IF	Citations
1	Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, 64-78.	1.3	7
2	Immunohistochemistry as a tool to identify ELP1-associated medulloblastoma. Acta Neuropathologica, 2022, 143, 523-525.	3.9	2
3	Intraâ€•and extraâ€cranial <scp>BCORâ€ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	1.3	10
4	Novel <scp>EWSR1::UBP1</scp> fusion expands the spectrum of spindle cell rhabdomyosarcomas. Genes Chromosomes and Cancer, 2022, 61, 200-205.	1.5	6
5	An obesogenic feedforward loop involving PPARÎ³, acyl-CoA binding protein and GABAA receptor. Cell Death and Disease, 2022, 13, 356.	2.7	5
6	Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. Molecular Cell, 2022, 82, 2458-2471.e9.	4.5	14
7	Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins. Cancers, 2022, 14, 2327.	1.7	8
8	Republication: Targeting PI3KC2Î² Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours. Anticancer Research, 2022, 42, 3217-3230.	0.5	2
9	INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing. Neuro-Oncology, 2022, 24, i189-i189.	0.6	0
10	BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells. Cancers, 2022, 14, 2755.	1.7	1
11	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47
12	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature Communications, 2021, 12, 3230.	5.8	95
13	ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion. Nucleic Acids Research, 2021, 49, 5038-5056.	6.5	11
14	Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. Cancer Discovery, 2021, 11, 2884-2903.	7.7	51
15	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	0.8	30
16	<scp>SMARCA4</scp>â€deficient rhabdoid tumours show intermediate molecular features between <scp>SMARCB1</scp>â€deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. Journal of Pathology, 2021, 255, 1-15.	2.1	14
17	STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma. Cancer Cell, 2021, 39, 810-826.e9.	7.7	48
18	Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT). Cancers, 2021, 13, 2904.	1.7	29

#	Article	IF	Citations
19	Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics). Journal of Molecular Diagnostics, 2021, 23, 1380-1392.	1.2	15
20	Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells. Cancer Research, 2021, 81, 4994-5006.	0.4	35
21	Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis. European Journal of Cancer, 2021, 154, 277-287.	1.3	7
22	Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus. American Journal of Human Genetics, 2021, 108, 1590-1610.	2.6	9
23	Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Cancer Research, 2020, 80, 832-842.	0.4	31
24	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. PLoS ONE, 2020, 15, e0237792.	1.1	6
25	Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nature Communications, 2020, 11, 4629.	5.8	32
26	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	0.8	9
27	High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma. EBioMedicine, 2020, 53, 102702.	2.7	0
28	High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. Cancers, 2020, 12, 644.	1.7	16
29	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Research, 2020, 48, 2676-2693.	6.5	30
30	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	15.2	172
31	Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. Cell Reports, 2020, 30, 1767-1779.e6.	2.9	96
32	Title is missing!. , 2020, 15, e0237792.		0
33	Title is missing!. , 2020, 15, e0237792.		0
34	Title is missing!. , 2020, 15, e0237792.		0
35	Title is missing!. , 2020, 15, e0237792.		0
36	Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. International Journal of Cancer, 2019, 144, 68-79.	2.3	37

#	Article	IF	Citations
37	STAG Mutations in Cancer. Trends in Cancer, 2019, 5, 506-520.	3.8	38
38	An autocrine ActivinB mechanism drives <scp>TGF</scp> Î²/Activin signaling in Group 3 medulloblastoma. EMBO Molecular Medicine, 2019, 11, e9830.	3.3	13
39	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell, 2019, 36, 597-612.e8.	7.7	100
40	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. Oncotarget, 2019, 10, 4937-4950.	0.8	5
41	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nature Communications, 2019, 10, 4128.	5.8	51
42	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports, 2019, 29, 104-117.e4.	2.9	16
43	ART-DeCo: easy tool for detection and characterization of cross-contamination of DNA samples in diagnostic next-generation sequencing analysis. European Journal of Human Genetics, 2019, 27, 792-800.	1.4	18
44	Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. International Journal of Cancer, 2019, 145, 2781-2791.	2.3	16
45	SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation. Acta Neuropathologica, 2019, 137, 675-678.	3.9	4
46	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	2.0	78
47	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1â€“TGF-Î²â€“OTX2â€“SNAIL via PTEN inhibition. Brain, 2018, 141, 1300-1319.	3.7	22
48	The ALK receptor in sympathetic neuron development and neuroblastoma. Cell and Tissue Research, 2018, 372, 325-337.	1.5	31
49	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics, 2018, 34, 1808-1816.	1.8	20
50	Transcriptomic definition of molecular subgroups of small round cell sarcomas. Journal of Pathology, 2018, 245, 29-40.	2.1	235
51	Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro-Oncology, 2018, 20, 1122-1132.	0.6	52
52	Activated ALK signals through the ERKâ€“ETV5â€“RET pathway to drive neuroblastoma oncogenesis. Oncogene, 2018, 37, 1417-1429.	2.6	45
53	Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients. European Journal of Human Genetics, 2018, 26, 1217-1221.	1.4	22
54	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. Cancer Cell, 2018, 33, 435-449.e6.	7.7	52

#	Article	IF	Citations
55	Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clinical Cancer Research, 2018, 24, 939-949.	3.2	127
56	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2018, 40, 93-98.	0.3	11
57	Biology of Bone and Soft Tissue Sarcoma: From Molecular Features to Clinical Applications. , 2018, , 134-134.		0
58	Genetic predisposition to medulloblastomas: just follow the tumour genome. Lancet Oncology, The, 2018, 19, 722-723.	5.1	2
59	PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. ELife, 2018, 7, .	2.8	39
60	Ewing sarcoma. Nature Reviews Disease Primers, 2018, 4, 5.	18.1	500
61	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics, 2018, 17, 1902-1916.	1.9	48
62	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. Nature Communications, 2018, 9, 3184.	5.8	50
63	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. American Journal of Pathology, 2018, 188, 2378-2391.	1.9	12
64	Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. Oncotarget, 2018, 9, 10175-10183.	0.8	23
65	Kids Enter the MATCH. Journal of the National Cancer Institute, 2017, 109, djw305.	3.0	1
66	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine, 2017, 23, 386-395.	15.2	193
67	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	3.4	376
68	Editorial overview: Characterizing the cancer genome: mechanistic insights and translational opportunities. Current Opinion in Genetics and Development, 2017, 42, 78-80.	1.5	1
69	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. Cancer Research, 2017, 77, 3666-3671.	0.4	93
70	MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death and Disease, 2017, 8, e2895-e2895.	2.7	226
71	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26365.	0.8	56
72	MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Cancer Letters, 2017, 385, 251-260.	3.2	30

#	Article	IF	Citations
73	Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nature Genetics, 2017, 49, 1408-1413.	9.4	331
74	Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor. European Journal of Human Genetics, 2017, 25, 1170-1172.	1.4	8
75	High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Reports, 2017, 21, 1737-1745.	2.9	32
76	A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. Npj Genomic Medicine, 2017, 2, .	1.7	17
77	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. Gene, 2017, 596, 137-146.	1.0	13
78	Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS ONE, 2017, 12, e0185190.	1.1	40
79	Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. Oncotarget, 2017, 8, 34245-34257.	0.8	13
80	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget, 2017, 8, 34141-34163.	0.8	72
81	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	0.8	55
82	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalinâ€Fixed Paraffinâ€Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	0.8	13
83	SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. Pediatric Blood and Cancer, 2016, 63, 568-569.	0.8	12
84	Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Nonâ€Polyalanine Repeat Expansion Mutations. Pediatric Blood and Cancer, 2016, 63, 71-77.	0.8	14
85	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clinical Cancer Research, 2016, 22, 5564-5573.	3.2	108
86	The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nature Communications, 2016, 7, 10421.	5.8	92
87	Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. European Urology, 2016, 69, 1055-1061.	0.9	96
88	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	3.0	71
89	Cooperation between somatic mutations and germline susceptibility variants in tumorigenesis â€“ a dangerous liaison. Molecular and Cellular Oncology, 2016, 3, e1086853.	0.3	11
90	68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. Anticancer Research, 2016, 36, 4459-4466.	0.5	10

#	Article	IF	Citations
91	Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development. Journal of Neuroscience, 2015, 35, 16531-16544.	1.7	32
92	Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nature Genetics, 2015, 47, 1073-1078.	9.4	157
93	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	9.4	451
94	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. Journal of Cell Biology, 2015, 208, 913-929.	2.3	224
95	Translational Activation of HIF1Î± by YB-1 Promotes Sarcoma Metastasis. Cancer Cell, 2015, 27, 682-697.	7.7	226
96	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Clinical Cancer Research, 2015, 21, 3327-3339.	3.2	76
97	Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. Clinical Cancer Research, 2015, 21, 4913-4921.	3.2	62
98	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3036-3046.	0.8	516
99	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	9.4	252
100	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	9.6	242
101	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	3.2	80
102	Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN. PLoS ONE, 2014, 9, e101990.	1.1	17
103	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	0.8	176
104	SegAnnDB: interactive Web-based genomic segmentation. Bioinformatics, 2014, 30, 1539-1546.	1.8	10
105	A siRNA screen identifies RAD21 , EIF3H , CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis, 2014, 35, 670-682.	1.3	44
106	Schwannomatosis Following an Early Rhabdoid Tumour of the Kidney: The Two Conditions May Coincide. Cancer Genetics, 2014, 207, 460.	0.2	0
107	Rhabdoid Tumours of Brain, Liver, Kidney and Soft-Parts: Expression Profiles Suggest Common Features but Different Entities.. Cancer Genetics, 2014, 207, 448.	0.2	1
108	Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. Breast Cancer Research, 2014, 16, R46.	2.2	40

#	Article	IF	Citations
109	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
110	Ewingâ€like sarcomas with BCORâ€CCNB3 fusion transcript: A clinical, radiological and pathological retrospective study from the SociÃ©tÃ© FranÃ§aise des Cancers de L'Enfant. Pediatric Blood and Cancer, 2014, 61, 2191-2198.	0.8	108
111	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	0.8	33
112	Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery, 2014, 4, 1342-1353.	7.7	418
113	Recent insights into the biology of neuroblastoma. International Journal of Cancer, 2014, 135, 2249-2261.	2.3	91
114	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	0.8	263
115	Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice. Oncotarget, 2014, 5, 2703-2713.	0.8	6
116	Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 2688-2702.	0.8	89
117	Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget, 2014, 5, 4452-4466.	0.8	32
118	Superficial EWSR1-negative undifferentiated small round cell sarcoma with CIC/DUX4 gene fusion: a new variant of Ewing-like tumors with locoregional lymph node metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 837-842.	1.4	52
119	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. American Journal of Human Genetics, 2013, 92, 974-980.	2.6	239
120	Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma. Cancer Research, 2013, 73, 195-204.	0.4	54
121	Germline mutations in FGF receptors and medulloblastomas. American Journal of Medical Genetics, Part A, 2013, 161, 382-385.	0.7	5
122	MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genetics, 2013, 206, 124-129.	0.2	13
123	PPAPDC1B and WHSC1L1 Are Common Drivers of the 8p11-12 Amplicon, Not Only in Breast Tumors But Also in Pancreatic Adenocarcinomas and Lung Tumors. American Journal of Pathology, 2013, 183, 1634-1644.	1.9	32
124	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
125	Wilmsâ€™ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. European Journal of Human Genetics, 2013, 21, 784-787.	1.4	26
126	Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Research, 2013, 41, 8853-8871.	6.5	45

#	Article	IF	Citations
127	ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics. Cancer Research, 2013, 73, 2905-2915.	0.4	56
128	Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial Sarcomas. Journal of Clinical Oncology, 2013, 31, 608-615.	0.8	135
129	Learning smoothing models of copy number profiles using breakpoint annotations. BMC Bioinformatics, 2013, 14, 164.	1.2	33
130	Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis. PLoS ONE, 2013, 8, e72182.	1.1	42
131	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. PLoS ONE, 2013, 8, e76496.	1.1	16
132	The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, 54.	1.3	32
133	High Frequency of Germline SUFU Mutations in Children With Desmoplastic/Nodular Medulloblastoma Younger Than 3 Years of Age. Journal of Clinical Oncology, 2012, 30, 2087-2093.	0.8	106
134	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. European Journal of Human Genetics, 2012, 20, 291-297.	1.4	38
135	Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation. Cancer Research, 2012, 72, 5454-5462.	0.4	515
136	Reply to S. Stegmaier et al. Journal of Clinical Oncology, 2012, 30, 4040-4041.	0.8	4
137	Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-Î² Abolishes Ewing Sarcoma Growth. Cancer Research, 2012, 72, 4494-4503.	0.4	59
138	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
139	PHOX2B Immunolabeling. American Journal of Surgical Pathology, 2012, 36, 1141-1149.	2.1	55
140	SMARCB1 Deficiency in Tumors From the Peripheral Nervous System. American Journal of Surgical Pathology, 2012, 36, 964-972.	2.1	38
141	Conventional Chondrosarcoma in a Survivor of Rhabdoid Tumor. American Journal of Surgical Pathology, 2012, 36, 1892-1896.	2.1	22
142	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. Journal of Neuro-Oncology, 2012, 109, 415-423.	1.4	13
143	Oncostatin M Is a Growth Factor for Ewing Sarcoma. American Journal of Pathology, 2012, 181, 1782-1795.	1.9	36
144	Antagonism Pattern Detection between MicroRNA and Target Expression in Ewingâ€™s Sarcoma. PLoS ONE, 2012, 7, e41770.	1.1	7

#	Article	IF	Citations
145	A Probabilistic Model for Cell Population Phenotyping Using HCS Data. PLoS ONE, 2012, 7, e42715.	1.1	5
146	A wholeâ€genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptorâ€negative and â€positive breast cancers. Journal of Pathology, 2012, 227, 29-41.	2.1	58
147	Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483, 570-575.	13.7	2,173
148	PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology, 2012, 30, 1670-1677.	0.8	297
149	Desmoplastic small round cell tumors with EWSâ€WT1 fusion transcript in children and young adults. Pediatric Blood and Cancer, 2012, 58, 891-897.	0.8	45
150	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327.	9.4	160
151	A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nature Genetics, 2012, 44, 461-466.	9.4	406
152	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	3.9	863
153	SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology, 2012, 61, 428-435.	1.6	105
154	Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Research, 2012, 14, R11.	2.2	160
155	Fineâ€needle aspiration as a diagnostic technique in 50 cases of primary Ewing sarcoma/peripheral neuroectodermal tumor. Institut Curie's experience. Diagnostic Cytopathology, 2012, 40, 19-25.	0.5	51
156	Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment. PLoS ONE, 2012, 7, e33581.	1.1	27
157	Targeting PI3KC2Î² impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours. Anticancer Research, 2012, 32, 3015-27.	0.5	29
158	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-Oncology, 2011, 103, 221-230.	1.4	21
159	Homozygous PTEN deletion in neuroblastoma arising in a child with Cowden syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 1763-1766.	0.7	3
160	Germline gain-of-function mutations of ALK disrupt central nervous system development. Human Mutation, 2011, 32, 272-276.	1.1	38
161	A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110Î³ Isoform in Medulloblastoma Cell Proliferation and Chemoresistance. Molecular Cancer Research, 2011, 9, 925-935.	1.5	56
162	Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development (Cambridge), 2011, 138, 4699-4708.	1.2	72

#	Article	IF	Citations
163	Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clinical Cancer Research, 2011, 17, 31-38.	3.2	191
164	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, 2011, 29, 1424-1430.	0.8	609
165	Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics, 2011, 27, 268-269.	1.8	249
166	Localizing potentially active post-transcriptional regulations in the Ewing's sarcoma gene regulatory network. BMC Systems Biology, 2010, 4, 146.	3.0	4
167	Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Molecular Medicine, 2010, 2, 211-230.	3.3	261
168	A prognostic DNA signature for T1T2 nodeâ€negative breast cancer patients. Genes Chromosomes and Cancer, 2010, 49, 1125-1134.	1.5	64
169	Arrayâ€Based Genomics in Glioma Research. Brain Pathology, 2010, 20, 28-38.	2.1	13
170	Reply to J.R. Anderson et al. Journal of Clinical Oncology, 2010, 28, e589-e590.	0.8	2
171	Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival. Clinical Cancer Research, 2010, 16, 2363-2374.	3.2	57
172	SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics, 2010, 26, 1895-1896.	1.8	178
173	Fusion Geneâ€"Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 2151-2158.	0.8	426
174	Prognostic Impact of Gene Expressionâ€"Based Classification for Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3506-3515.	0.8	129
175	De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Research, 2010, 38, e126-e126.	6.5	62
176	Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. Journal of Medical Genetics, 2010, 47, 859-862.	1.5	57
177	Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-Oncology, 2010, 12, 153-163.	0.6	72
178	Impact of EWS-ETS Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial. Journal of Clinical Oncology, 2010, 28, 1982-1988.	0.8	180
179	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3122-3130.	0.8	142
180	Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. Journal of Medical Genetics, 2010, 47, 142-144.	1.5	51

#	Article	IF	Citations
181	Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients. Cancer Research, 2010, 70, 7610-7619.	0.4	73
182	Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. European Journal of Cancer, 2010, 46, 2399-2407.	1.3	54
183	EWS-FLI1 inhibits TNFÎ±-induced NFÎºB-dependent transcription in Ewing sarcoma cells. Biochemical and Biophysical Research Communications, 2010, 399, 705-710.	1.0	5
184	Unexpected diagnosis for an adrenal tumor: synovial sarcoma. Annals of Diagnostic Pathology, 2010, 14, 56-59.	0.6	7
185	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	3.2	86
186	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	3.2	243
187	Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Research, 2010, 30, 4229-35.	0.5	29
188	NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas. PLoS ONE, 2009, 4, e4107.	1.1	19
189	MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma. PLoS ONE, 2009, 4, e4998.	1.1	233
190	DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Human Molecular Genetics, 2009, 18, 1405-1414.	1.4	128
191	Syndrome de prÃ©disposition aux tumeurs rhabdoÃ¯des. , 2009, , 281-286.		0
192	High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors. Cancer Research, 2009, 69, 663-671.	0.4	136
193	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. Journal of Clinical Oncology, 2009, 27, 1026-1033.	0.8	288
194	Betaâ€catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. Journal of Pathology, 2009, 218, 86-94.	2.1	171
195	Cholinergic switch associated with morphological differentiation in neuroblastoma. Journal of Pathology, 2009, 219, 463-472.	2.1	26
196	VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the SociÃ©tÃ© FranÃ§aise des Cancers de l'Enfant (SFCE). Pediatric Blood and Cancer, 2009, 52, 585-590.	0.8	36
197	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	5.1	176
198	The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function. PLoS ONE, 2009, 4, e4932.	1.1	160

#	Article	IF	Citations
199	8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis. PLoS ONE, 2009, 4, e7239.	1.1	79
200	BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. International Journal of Cancer, 2008, 122, 1778-1786.	2.3	100
201	Alagille syndrome and nephroblastoma: Unusual coincidence of two rare disorders. Pediatric Blood and Cancer, 2008, 50, 908-911.	0.8	11
202	Extraâ€renal nonâ€cerebral rhabdoid tumours. Pediatric Blood and Cancer, 2008, 51, 363-368.	0.8	80
203	Intracerebral small round cell tumor: An unusual case with EWSâ€WT1 translocation. Pediatric Blood and Cancer, 2008, 51, 545-548.	0.8	13
204	Characterization of amplicons in neuroblastoma: Highâ€resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes and Cancer, 2008, 47, 819-834.	1.5	39
205	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 2008, 455, 967-970.	13.7	787
206	ESR1 gene amplification in breast cancer: a common phenomenon?. Nature Genetics, 2008, 40, 809-809.	9.4	46
207	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology, 2008, 28, 440-443.	0.7	29
208	Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6004-6009.	3.3	85
209	RhoA-Dependent Regulation of Cell Migration by the Tumor Suppressor hSNF5/INI1. Cancer Research, 2008, 68, 6154-6161.	0.4	49
210	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. Cancer Research, 2008, 68, 7165-7175.	0.4	83
211	Coupled alteration of transcription and splicing by a single oncogene: Boosting the effect on cyclin D1 activity. Cell Cycle, 2008, 7, 2299-2305.	1.3	32
212	Targeting the PI3K p110Î± Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration. Clinical Cancer Research, 2008, 14, 6761-6769.	3.2	73
213	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast. Clinical Cancer Research, 2008, 14, 1956-1965.	3.2	148
214	Primary Desmoplastic Small round Cell Tumor of the Kidney: A Case Report in a 14-Year-Old Girl with Molecular Confirmation. Pediatric and Developmental Pathology, 2007, 10, 320-324.	0.5	16
215	A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays. Clinical Cancer Research, 2007, 13, 3989-3998.	3.2	364
216	Extraosseous Localized Ewing Tumors: Improved Outcome With Anthracyclinesâ€"The French Society of Pediatric Oncology and International Society of Pediatric Oncology. Journal of Clinical Oncology, 2007, 25, 1176-1182.	0.8	57

#	Article	IF	Citations
217	Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochemical Journal, 2007, 406, 57-66.	1.7	47
218	Rapid Development of an Osteosarcoma After Surgical Resection of an Osteochondroma. Journal of Pediatric Orthopaedics, 2007, 27, 640-642.	0.6	2
219	Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma. European Journal of Cancer, 2007, 43, 2366-2372.	1.3	20
220	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Research, 2007, 9, R24.	2.2	154
221	Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatric Blood and Cancer, 2007, 48, 311-317.	0.8	41
222	Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genetics and Cytogenetics, 2007, 176, 121-126.	1.0	15
223	JUN Oncogene Amplification and Overexpression Block Adipocytic Differentiation in Highly Aggressive Sarcomas. Cancer Cell, 2007, 11, 361-374.	7.7	175
224	Mesenchymal Stem Cell Features of Ewing Tumors. Cancer Cell, 2007, 11, 421-429.	7.7	457
225	The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. European Journal of Cancer, 2006, 42, 2326-2334.	1.3	38
226	Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: Evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. Genes Chromosomes and Cancer, 2006, 45, 495-508.	1.5	18
227	The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. International Journal of Cancer, 2006, 118, 1381-1389.	2.3	75
228	VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics, 2006, 22, 2066-2073.	1.8	106
229	Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene, 2005, 24, 3377-3384.	2.6	36
230	Chromosome mechanisms and INI1 inactivation in human and mouse rhabdoid tumors. Cancer Genetics and Cytogenetics, 2005, 157, 127-133.	1.0	13
231	An aggressive Ewing sarcoma associated with a new variant translocation, t(4;11;22)(q25;q24;q12), hyperdiploid karyotype, and tetrasomy 8. Cancer Genetics and Cytogenetics, 2005, 163, 186-188.	1.0	2
232	Two types of chromosome 1p losses with opposite significance in gliomas. Annals of Neurology, 2005, 58, 483-487.	2.8	157
233	Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genesâ€"A Study of 130 Invasive Ductal Breast Carcinomas. Cancer Research, 2005, 65, 1376-1383.	0.4	62
234	Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma. Cell Cycle, 2005, 4, 1842-1846.	1.3	33

#	Article	IF	Citations
235	Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Research, 2005, 65, 11520-11528.	0.4	187
236	Complementation analyses suggest species-specific functions of the SNF5 homology domain. Biochemical and Biophysical Research Communications, 2005, 336, 634-638.	1.0	2
237	P23: CAP: aÂWeb-based platform forÂCGH-array management andÂanalysis. European Journal of Medical Genetics, 2005, 48, 471-472.	0.7	0
238	Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Letters, 2005, 228, 51-58.	3.2	63
239	Protein interaction mapping: A Drosophila case study. Genome Research, 2005, 15, 376-384.	2.4	509
240	EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3. Molecular and Cellular Biology, 2004, 24, 7275-7283.	1.1	376
241	The Tumor Suppressor hSNF5/INI1 Modulates Cell Growth and Actin Cytoskeleton Organization. Cancer Research, 2004, 64, 3406-3413.	0.4	88
242	Claes Lundsteenâ€"in Memoriam. European Journal of Human Genetics, 2004, 12, 603-603.	1.4	0
243	Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma. Oncogene, 2004, 23, 2420-2430.	2.6	31
244	Gene expression profiling of 1p35â€"36 genes in neuroblastoma. Oncogene, 2004, 23, 5912-5922.	2.6	60
245	Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes and Cancer, 2004, 39, 143-150.	1.5	35
246	High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hybridization. Genes Chromosomes and Cancer, 2004, 40, 266-270.	1.5	13
247	High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma withMYCN amplification. Cancer, 2004, 101, 1081-1089.	2.0	49
248	Rhabdomyosarcoma: Value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype. Cancer, 2004, 101, 2817-2824.	2.0	66
249	Germline Mutations of the Pairedâ€"Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma. American Journal of Human Genetics, 2004, 74, 761-764.	2.6	288
250	Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 141, 32-42.	1.0	53
251	Expression and subcellular localization of Ewing sarcoma (EWS) protein is affected by the methylation process. Experimental Cell Research, 2003, 288, 374-381.	1.2	32
252	Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor. Journal of Clinical Oncology, 2003, 21, 85-91.	0.8	203

#	Article	IF	Citations
253	Molecular Detection of the Synovial Sarcoma Translocation t(X;18) by Real-Time Polymerase Chain Reaction in Paraffin-Embedded Material. Diagnostic Molecular Pathology, 2002, 11, 16-21.	2.1	31
254	Rhabdoid Tumor of the Kidney is a Component of the Rhabdoid Predisposition Syndrome. Pediatric and Developmental Pathology, 2002, 5, 395-399.	0.5	32
255	Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines. Oncogene, 2002, 21, 5654-5659.	2.6	36
256	A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene, 2002, 21, 6403-6412.	2.6	160
257	Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene, 2002, 21, 7700-7709.	2.6	73
258	Intraabdominal Desmoplastic Small Round Cell Tumor. Acta Cytologica, 2001, 45, 617-621.	0.7	41
259	Characterization of a new brain-specific isoform of the EWS oncoprotein. FEBS Journal, 2001, 268, 3483-3489.	0.2	17
260	Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?. Medical and Pediatric Oncology, 2001, 36, 5-10.	1.0	82
261	Intracranial Ewing sarcoma/'peripheral' primitive neuroectodermal tumor of dural origin with molecular genetic confirmation. Journal of Neuro-Oncology, 2001, 51, 51-56.	1.4	49
262	A Multiplex Real-Time PCR Assay for the Detection of Gene Fusions Observed in Solid Tumors. Laboratory Investigation, 2001, 81, 905-912.	1.7	112
263	Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Medicine, 2001, 7, 920-926.	15.2	124
264	Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene, 2001, 20, 3258-3265.	2.6	157
265	CGH analysis of secondary genetic changes in Ewing tumors:. Cancer Genetics and Cytogenetics, 2001, 130, 57-61.	1.0	39
266	Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes and Cancer, 2000, 28, 276-284.	1.5	26
267	Induction of p21Waf1/Cip1 by TNFÎ± requires NF-Î²B activity and antagonizes apoptosis in Ewing tumor cells. Oncogene, 2000, 19, 61-68.	2.6	60
268	IFN-Î² induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene, 2000, 19, 3372-3383.	2.6	114
269	Presence of new alternative exons in human and mouse Fli-1 genes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1517, 164-170.	2.4	4
270	Mutations of the hSNF5/INI1 Gene in Renal Rhabdoid Tumors With Second Primary Brain Tumors. Journal of the National Cancer Institute, 2000, 92, 648-650.	3.0	68

#	Article	IF	Citations
271	E1A and the Ewing tumor translocation. Nature Medicine, 1999, 5, 1331-1331.	15.2	6
272	Constitutional Mutations of the hSNF5/INI1 Gene Predispose to a Variety of Cancers. American Journal of Human Genetics, 1999, 65, 1342-1348.	2.6	409
273	Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature, 1998, 394, 203-206.	13.7	1,396
274	Cytogenetic and molecular analysis of a t(1;22)(p36;q11.2) in a rhabdoid tumor with a putative homozygous deletion of chromosome 22. , 1998, 21, 82-89.		41
275	EWS, but Not EWS-FLI-1, Is Associated with Both TFIID and RNA Polymerase II: Interactions between Two Members of the TET Family, EWS and hTAF_{II}68, and Subunits of TFIID and RNA Polymerase II Complexes. Molecular and Cellular Biology, 1998, 18, 1489-1497.	1.1	230
276	The Prooncoprotein EWS Binds Calmodulin and Is Phosphorylated by Protein Kinase C through an IQ Domain. Journal of Biological Chemistry, 1997, 272, 27369-27377.	1.6	68
277	Production and Characterization of Mouse Monoclonal Antibodies to Wild-Type and Oncogenic FLI-1 Proteins. Hybridoma, 1997, 16, 457-464.	0.9	26
278	A new member of the ETS family fused to EWS in Ewing tumors. Oncogene, 1997, 14, 1159-1164.	2.6	372
279	Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Human Genetics, 1997, 99, 357-363.	1.8	51
280	Polymerase chain reaction compared with dot blotting for the determination of N-myc gene amplification in neuroblastoma. , 1997, 72, 518-521.		20
281	Chromosome Translocations Generating Chimeric Transcription Factors, Unique Genetic Events with Pleiotropic Cellular Consequences. , 1997, , 77-105.		0
282	Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. , 1996, 69, 73-78.		34
283	AnEWS/ERG fusion with a truncated N-terminal domain ofEWS in a Ewing's tumor. , 1996, 67, 339-342.		19
284	Analysis of theNF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. International Journal of Cancer, 1995, 60, 478-481.	2.3	47
285	Screening for germ-line mutations in theNF2 Gene. Genes Chromosomes and Cancer, 1995, 12, 117-127.	1.5	128
286	Evidence for two tumour suppressor loci on chromosomal bands 1p35â€“36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Human Molecular Genetics, 1995, 4, 535-539.	1.4	154
287	Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Human Molecular Genetics, 1995, 4, 2219-2226.	1.4	190
288	The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts. New England Journal of Medicine, 1994, 331, 294-299.	13.9	1,010

#	Article	IF	Citations
289	Refined mapping of eight cosmid markers on human chromosome 22. Japanese Journal of Human Genetics, 1994, 39, 243-248.	0.8	3
290	Two distinct deleted regions on the short arm of chromosome I in neuroblastoma. Genes Chromosomes and Cancer, 1994, 10, 275-281.	1.5	144
291	Analysis of mutations in theSCH gene in schwannomas. Genes Chromosomes and Cancer, 1994, 11, 7-14.	1.5	57
292	Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genetics, 1994, 6, 180-184.	9.4	514
293	Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genetics and Cytogenetics, 1994, 74, 13-18.	1.0	67
294	Physical Mapping of the NF2/Meningioma Region on Human Chromosome 22q12. Genomics, 1994, 19, 52-59.	1.3	18
295	Cloning and Chromosome Localization of the Mouse Ews Gene. Genomics, 1994, 23, 278-281.	1.3	6
296	Regional fine mapping of the Î² crystallin genes on chromosome 22 excludes these genes as physically linked markers for neurofibromatosis type 2. Genes Chromosomes and Cancer, 1993, 8, 112-118.	1.5	10
297	Subregional physical mapping of an ?B-crystallin sequence and of a new expressed sequence D11S877E to human 11q. Mammalian Genome, 1993, 4, 104-108.	1.0	12
298	Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 1993, 363, 515-521.	13.7	1,351
299	EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genetics, 1993, 4, 341-345.	9.4	483
300	Mapping of Human Î³-Glutamyl Transpeptidase Genes on Chromosome 22 and Other Human Autosomes. Genomics, 1993, 17, 299-305.	1.3	36
301	Isolation and Mapping of 45 NotI Linking Clones to Chromosome 22. Genomics, 1993, 17, 776-779.	1.3	1
302	Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics, 1993, 18, 609-615.	1.3	94
303	The Genes for Oncostatin M (OSM) and Leukemia Inhibitory Factor (LIF) Are Tightly Linked on Human Chromosome 22. Genomics, 1993, 17, 136-140.	1.3	52
304	Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Human Molecular Genetics, 1993, 2, 1215-1220.	1.4	60
305	Isolation of cosmids and fetal brain cDNAs from the proximal long arm of human chromosome 22. Human Molecular Genetics, 1993, 2, 535-540.	1.4	8
306	Reverse Transcriptase PCR Amplification of EWS/FLI-1 Fusion Transcripts as a Diagnostic Test for Peripheral Primitive Neuroectodermal Tumors of Childhood. Diagnostic Molecular Pathology, 1993, 2, 147-157.	2.1	91

#	Article	IF	Citations
307	Survival and acquired genetic alterations in colorectal cancer. Gastroenterology, 1992, 102, 1136-1141.	0.6	182
308	Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics, 1992, 13, 881-883.	1.3	32
309	Cloning of six new genes with zinc finger motifs mapping to short and long arms of human acrocentric chromosome 22 (p and q11.2). Genomics, 1992, 13, 641-648.	1.3	28
310	Rapid isolation of cosmids from defined subregions by differential Alu-PCR hybridization on chromosome 22-specific library. Genomics, 1992, 13, 395-401.	1.3	14
311	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 1992, 359, 162-165.	13.7	1,724
312	Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes and Cancer, 1992, 5, 271-277.	1.5	284
313	Allelic loss on chromosome 22 correlates with histopathological predictors of recurrence of meningiomas. International Journal of Cancer, 1992, 50, 391-394.	2.3	30
314	PCR assay for chromosome 1p deletion in small neuroblastoma samples. International Journal of Cancer, 1992, 52, 544-548.	2.3	53
315	Parental origin of chromosome 22 loss in sporadic and NF2 neuromas. Genomics, 1991, 10, 280-283.	1.3	23
316	Mapping of human chromosome 22 with a panel of somatic cell hybrids. Genomics, 1991, 9, 721-727.	1.3	60
317	Cytogenetic and molecular approaches of polyploidization in colorectal adenocarcinomas. Cancer Genetics and Cytogenetics, 1990, 44, 107-118.	1.0	41
318	RFLP identified by the anonymous DNA segment OLVIIF5 at 21q22.1-22.3 [HGM9 no.D21S143]. Nucleic Acids Research, 1989, 17, 1790-1790.	6.5	0
319	RFLP identified by the anonymous DNA segment OLVIIDI on chromosome 6 [HGM9 no.D6S47]. Nucleic Acids Research, 1989, 17, 1789-1789.	6.5	0
320	RFLP identified by the anonymous DNA segment FL V D11 at 22q13 [HGM9 no.D22S80]. Nucleic Acids Research, 1989, 17, 1791-1791.	6.5	2
321	Preservation of chromosome and DNA characteristics of human colorectal adenocarcinomas after passage in nude mice. International Journal of Cancer, 1989, 44, 871-878.	2.3	21
322	RFLP identified by the anonymous DNA segment FZ VI 4.2 at 22q11.2 [HGM no. D22S20]. Nucleic Acids Research, 1988, 16, 2739-2739.	6.5	4
323	RFLP identified by the anonymous DNA segment OL VII A8 at 18q11 (HGM8 do. D18S7). Nucleic Acids Research, 1987, 15, 1343-1343.	6.5	15
324	RFLP identified by the anonymous DNA segment OL VII E10 at 18q21.3 (HGM do. D18S8). Nucleic Acids Research, 1987, 15, 1348-1348.	6.5	19

#	Article	IF	Citations
325	HighhThroughput Drug Screening Identifies Pazopanib and Clofilium Tosylate As Promising Treatments for Malignant Rhabdoid Tumors. SSRN Electronic Journal, 0, , .	0.4	0